張曉明

個人簡介

張曉明，免疫學博士🤷🏿‍♀️，入選國家級領軍人才，擔任科技部重點研發計劃首席科學家👦🏽，中國科沐鸣2分子病毒與免疫重點實驗室副主任。2007年於法國巴黎第六大學獲得博士學位，2007年至2012年於法國巴斯德研究所進行博士後研究💁。目前發表SCI論文60余篇。主持國家科技部重點研發計劃1項，中國科沐鸣2前沿科學重點研究計劃1項，中科院戰略先導項目課題1項🧘🏽‍♂️，國家自然科學基金重點類項目1項、集成項目課題1項、面上項目3項，上海市科委項目4項等項目。

研究方向

1. 腫瘤免疫治療新靶點與治療性疫苗

2. B細胞與創新抗體發現

榮譽及獲獎情況

1. 上海市優秀學術帶頭人—2023年

2. 中國科沐鸣2前沿科學重點研究計劃-“拔尖青年科學家”—2016年

3. 中國科沐鸣2創新交叉團隊負責人—2014年

4. 上海市科技啟明星計劃—2012年

5. 國家海外高層次青年人才—2011年

主持與承擔主要項目情況

1. 科技部重點研發計劃：新冠病毒抗體依賴性增強作用(ADE)抗體的篩選及潛在致病機製研究，主持；

2. 國家自然科學基金（集成項目）：解析肝癌免疫微環境的時空演進特征以指導肝癌精準診療的研究🕖，課題主持🌂；

3. 國家自然科學基金（國際合作重點項目）：類風濕性關節炎疾病特異性淋巴細胞及分子的系統解析，主持🐻；

4. 國家自然科學基金（面上項目）🧑🏻‍🦼‍➡️：mTORC1通路在B1a細胞命運決定中的作用及其分子調控機製研究，主持；

5. 中國科沐鸣2前沿科學重點項目：肝癌免疫微環境的系統解析和新型免疫靶標的發現，主持；

6. 中國科沐鸣2戰略性先導科技專項課題：肝癌免疫細胞圖譜的繪製和抗體免疫應答的機製解析😬，主持🏊🏽‍♀️；

7. 上海市優秀學術帶頭人項目👩🏻‍🔬：自身反應性B細胞異常分化的分子機製研究👨🏻‍🦯‍➡️，主持❤️‍🔥。

發表論著情況

1. Ma JQ, Wu YC, Ma LF, Yang XP, Zhang TC, Song GH, Li T, Gao K, Shen X, Lin J, Chen YM, Liu XS, F YT, Gu XX, Chen ZC, Jiang S, Rao DN, Pan JM, Zhang S, Zhou J, Huang C, Shi S, Fan J*, Guo GJ*, Zhang XM*, and Qiang Gao*. A blueprint for tumor-infiltrating B cells across human cancers. Science. 2024, 384, eadj4857. [IF=56.9]

2. Wu YC, Ma JQ, XP, Fang Nan F, Zhang TC, Ji SY, Rao DN, Feng H, Gao K, Gu XX, Jiang S, Song GH, Pan JM, Zhang M, Xu YN, Zhang S, Fan YH, Wang XY, Zhou J, Yang L*, Jia Fan J*, Zhang XM*, and Gao Q*. Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell. 2024, 187:1422–1439. [IF=64.5]

3. Dong C, Guo YC, Chen ZC, Li T, Ji J, Sun C, Li J, Cao HX, Xia YF, Xue ZH, Gu XX, Liang Q, Zhao R, Fu T, Ma JQ, Jiang S, Wu CM, Fu Q, Guo GK, Bao YF, Guo H, Yang JL, Xu M, Zhang XM*, Sheng ZZ*, and Gu ZF*. Single-cell profiling of bone marrow B cells uncovers early B cell developmental disorders associated with systemic lupus erythematosus. Arthritis Rheumatol. 2024, 76(4): 599-613. [IF=13.3]

4. Meng L, Zha JL, Zhou BJ, Cao L, Jiang CL, Zhu YF, Li T, Lu L, Zhang JQ, Yang H, Feng J, Gu ZF, Tang H, Jiang LB, Li DF*, Lavillette D*, and Zhang XM*. A Spike-destructing human antibody effectively neutralizes Omicron- included SARS-CoV-2 variants with therapeutic efficacy. PLoS Pathog. 2023, 19(1): e1011085. [IF=7.464]

5. Bao SH, Chen ZC, Qin DK, Xu HH, Deng XJ, Zhang RX, Ma JQ, Lu ZP, Jiang S, and Zhang XM*. Single-cell profiling reveals mechanisms of uncontrolled inflammation and glycolysis in decidual stromal cell subtypes in recurrent miscarriage. Hum Reprod. 2023, 38(1): 57-74. [IF=6.353]

6. Ye Y, Chen ZC, Jiang S, Jia FY, Li T, Lu X, Xue, J, Lian XY, Ma JQ, Hao P, Lu LJ, Ye S, Shen N, Bao CD, Fu Q* and Zhang XM*. Single-cell Profiling Reveals Distinct Adaptive Immune Hallmarks in MDA5+ Dermatomyositis with Therapeutic Implications. Nat Commun. 2022, 13: 6458. [IF=17.694]

7. Ye Y, Zhang XL, Li T, Ma JQ, Wang R, Wu CM, Wang RC, Bao CD, Ye S, Shen N, Guo Q*, Fu Q* and Zhang XM*. Two Distinct Immune Cell Signatures Predict the Clinical Outcomes in Patients with MDA5 positive Dermatomyositis with Interstitial Lung Disease. Arthritis Rheumatol. 2022, 74: 1822–1832. [IF=13.3]

8. Wu YC, Yang SX, Ma JQ, Chen ZC, Song GH, Rao DN, Cheng YF, Huang SY, Liu YF, Jiang S, Liu JX, Huang XW, Wang XY, Qiu SJ, Xu JM, Xi RB, Bai F, Zhou J, Fan J, Zhang XM*, and Gao Q*. Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level. Cancer Discov. 2022, 12 (1): 134-153. [IF=38.272]

9. Song GH, Shi Y, Meng L, Ma JQ, Huang SY, Zhang J, Wu YC, Li JX, Lin YP, Yang SX, Rao DN, Cheng YF, Lin J, Ji SY, Liu YM, Jiang S, Wang XL, Zhang S, Ke AW, Wang XY, Cao Y, Ji Y, Zhou J, Fan J*, Zhang XM*, Xi RB*, and Gao Q*. Single-Cell Transcriptomic Analysis Reveals Two Molecularly and Clinically Distinct Subtypes of Intrahepatic Cholangiocarcinoma. Nat Commun. 2022, 13: 1642 [IF=17.694]

10. Song GH, Shi Y, Zhang MY, Goswami S, Afridi S, Meng L, Ma JQ, Chen Y, Lin YP, Zhang J, Liu YM , Jin ZJ , Yang SX, Rao DN, Zhang S, Ke AW, Wang XY, Cao Y, Zhou J, Fan J, Zhang XM*, Xi RB*, and Gao Q*. Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T cell subsets associated with disease progression. Cell Discov. 2020, 6:90. [IF=38.079]

11. Yang HJ, Ye S, Goswami S, Li T, Wu JW, Cao CM, Ma JQ, Lu B, Pei X, Chen YN, Yu J, Xu HH, Qiu LW, Afridi S, Xiang LB and Zhang XM*. Highly immunosuppressive HLADRhi regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma. Int J Cancer. 2020, 146: 1993-2006. [IF=7.316]

12. Duan M, Goswami S, Shi JY, Wu LJ, Wang XY, Ma JQ, Zhang Z, Shi Y, Ma LJ, Zhang S, Xi RB, Cao Y, Zhou J, Fan J*, Zhang XM* and Gao Q*. Activated and exhausted MAIT cells foster disease progression and indicate poor outcome in hepatocellular carcinoma. Clin Cancer Res. 2019, 25: 3304-3316. [IF=13.801]

13. Ma JQ, Zheng BH, Goswami S, Meng L, Zhang DD, Cao CM, Li T, Zhu FM, Ma LJ, Zhang Z, Zhang SH, Duan M, Chen Q, Gao Q* and Zhang XM*. PD1HiCD8+T Cells Correlate with Exhausted Signature and Poor Clinical Outcome in Hepatocellular Carcinoma. J ImmunoTher Cancer. 2019, 7: 331.[IF=12.469]

14. Wu CM, Fu Q, Guo Q, Chen S, Goswami S, Sun SH, Li T, Cao XJ, Chu FY, Chen ZC, Liu M, Liu YH, Fu T, Hao P, Hao Y, Shen N, Bao CD*, and Zhang XM*. Lupus associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated. Ann Rheum Dis. 2019, 78 (8): 1090-1100. [IF=27.973]

15. Liu M, Guo Q, Wu CM, Sterlin D, Goswami S, Zhang Y, Li T, Bao CD, Shen N, Fu Q*, and Zhang XM*. Type I interferons promote the survival and proinflammatory properties of transitional B cells in systemic lupus erythematosus patients. Cell Mol Immunol. 2019, 16: 367–379. [IF= 22.096]

16. Zhang Z, Ma LJ, Goswami S, Ma JQ, Zheng BH, Duan M, Liu LZ, Zhang LJ, Shi JY, Dong LQ, Sun YM, Tian LY, Gao Q*, and Zhang XM*. Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma. Oncoimmunology. 2019, 8(4): e1571388. [IF=7.723]

(*：通訊作者)

聯系方式

Email：xmzhang@siii.cas.cn 

辦公地址🧝🏻：嶽陽路320號/上海免疫與感染所B108室